Roka Bioscience Details IPO

The company is expected to complete its IPO this month. Plans for the use of the proceeds include $14.0 million in payments to Gen-Probe and $16.0 million for R&D.

Washington, DC 7/7/14—In a new filing with the SEC, Roka Bioscience provided additional details of its pending IPO (see IBO 5/31/14). The company plans to offer five million shares of common stock at a price of $14–$16 per share. Net proceeds are estimated to be $67.4 million, or $77.8 million if the overallotment option is fully exercised, based on the mid-point of the price range.

< | >